Halofantrine

CHEMBL1107 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

500.4 g/mol

LogP

8.6

Phase

4

An antimalarial medication used to treat malaria caused by chloroquine-resistant Plasmodium falciparum and P. vivax strains. It works by interfering with the parasite's heme detoxification process, leading to the accumulation of toxic heme within the parasite. Concerns about cardiotoxicity, particularly QT prolongation, limit its use to situations where safer alternatives are not available.

الوزن الجزيئي

500,4000 g/mol

LogP

8,60

TPSA

23,50 Å²

قاعدة ليبينسكي للخمسة

راسب

المجالات العلاجية

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Glaucoma Cardiovascular Disease Pain Management Non-Small Cell Lung Cancer Schizophrenia Generalized Anxiety Disorder Systemic Lupus Erythematosus Obesity Transplant Medicine Hypertension Major Depressive Disorder Breast Cancer Malaria HIV/AIDS Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12

InChI

InChI=1S/C26H30Cl2F3NO/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3

Molecular Formula

C26H30Cl2F3NO

HBD / HBA

1 / 5

الروابط القابلة للدوران

10

الذرات الثقيلة

33

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

An antimalarial medication used to treat malaria caused by chloroquine-resistant Plasmodium falciparum and P. vivax strains. It works by interfering with the parasite's heme detoxification process, leading to the accumulation of toxic heme within the parasite. Concerns about cardiotoxicity, particularly QT prolongation, limit its use to situations where safer alternatives are not available.

Yes, Halofantrine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1107. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 37393. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Halofantrine على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C26H30Cl2F3NO

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.